Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future.
|Interactive Analyst Center|
Investors and analysts can access Exelixis' historical financial reports, including income statements and balance sheets, export reports, build custom charts and view a historical stock chart.